A detailed history of Franklin Resources Inc transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Franklin Resources Inc holds 2,786,335 shares of PCVX stock, worth $255 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
2,786,335
Previous 2,786,335 -0.0%
Holding current value
$255 Million
Previous $318 Million -0.0%
% of portfolio
0.1%
Previous 0.09%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$70.52 - $117.12 $22.9 Million - $38 Million
324,560 Added 13.18%
2,786,335 $318 Million
Q2 2024

Aug 14, 2024

BUY
$60.06 - $78.77 $18.9 Million - $24.7 Million
314,119 Added 14.63%
2,461,775 $186 Million
Q1 2024

May 13, 2024

BUY
$59.79 - $81.05 $64 Million - $86.8 Million
1,070,736 Added 99.43%
2,147,656 $147 Million
Q4 2023

Feb 09, 2024

BUY
$45.35 - $63.41 $5.49 Million - $7.67 Million
120,985 Added 12.66%
1,076,920 $67.6 Million
Q3 2023

Nov 13, 2023

BUY
$46.0 - $53.1 $9.36 Million - $10.8 Million
203,536 Added 27.05%
955,935 $48.7 Million
Q2 2023

Aug 11, 2023

BUY
$34.66 - $54.07 $1.25 Million - $1.96 Million
36,160 Added 5.05%
752,399 $37.6 Million
Q1 2023

May 12, 2023

BUY
$36.27 - $47.2 $25.8 Million - $33.6 Million
711,039 Added 13673.83%
716,239 $26.8 Million
Q4 2022

Feb 10, 2023

BUY
$20.58 - $47.95 $107,015 - $249,340
5,200 New
5,200 $249,000
Q1 2021

May 13, 2021

SELL
$18.66 - $29.16 $7.47 Million - $11.7 Million
-400,076 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$26.57 - $51.74 $159 - $310
6 Added 0.0%
400,076 $10.6 Million
Q2 2020

Aug 13, 2020

BUY
$26.15 - $35.45 $10.5 Million - $14.2 Million
400,070 New
400,070 $12.7 Million

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.43B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Franklin Resources Inc Portfolio

Follow Franklin Resources Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

News

Stay updated on Franklin Resources Inc with notifications on news.